All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Treatment-related cardiotoxicity in pediatric patients with acute myeloid leukemia treated in the AAML0531 clinical trial
Outcomes of pediatric patients with acute myeloid leukemia (AML) have significantly improved over the past several decades with overall survival (OS) rates now approaching 70%.1 Despite this improvement, anthracycline-associated cardiotoxicity, including left ventricular systolic dysfunction (LVSD), remains a serious risk for this patient population. Kelly D. Getz, PhD, of the Perelman School of Medicine, University of Pennsylvania, PA, USA, and colleagues analyzed pediatric patients with AML treated as part of COG AAML0531 trial in order to evaluate the independent effects of early-onset cardiotoxicity on event-free survival (EFS) or OS.2 The study was published in the Journal of Clinical Oncology on 1 January 2019.
The AAML0531 trial enrolled patients aged 30 or younger who were treated with intravenous infusions of daunorubicin and mitoxantrone. Cardiotoxicity was defined as grade 2 or higher LVSD on the basis of Common Terminology Criteria for Adverse Events definitions. Adverse events during a 5-year follow-up were monitored among 1,022 pediatric patients with AML.
Key findings
- About 12% of patients had cardiotoxicity reported; 71% of these events were first observed during on-protocol therapy
- The median time to cardiotoxicity was 4.3 months
- On-protocol cardiotoxicity was significantly correlated with subsequent off-protocol toxicity
- Patients with documented cardiotoxicity had significantly worse EFS: HR = 1.6 (95% CI, 1.2–2.1), P = 0.004
- Patients with documented cardiotoxicity had significantly inferior OS: HR = 1.6; 95% CI, 1.2–2.2), P = 0.005
- Effects on EFS were similar for those with infection-associated LVSD and those with LVSD without infection
- Reductions in OS were significantly worse for cardiotoxicity not associated with infection than those with infection-associated cardiotoxicity: HR = 1.7 (95% CI, 1.2–2.5), P = 0.004 vs HR = 1.3 (95% CI, 0.7–2.4), P = 0.387\
The study authors concluded that “early treatment-related cardiotoxicity may be associated with decreased EFS and OS. Cardioprotective strategies are urgently needed to improve relapse risk and both short- and long-term mortality outcomes.”
These findings are important to better understand cardiotoxicity risk factors and to reduce anthracycline-induced left ventricular dysfunction in children with AML. This significant decrease in EFS and its effect on OS highlights the necessity of prospective clinical trials to evaluate prophylactic interventions.
References